SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing ...

SUNNYVALE, Calif., Nov. 28, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough ...

Just a few weeks later than expected, Inflammatix Inc. secured U.S. FDA clearance of the Triverity test system for use in emergency triage of patients with suspected acute infection or sepsis. The ...

SUNNYVALE, Calif., Sept. 2, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced the publication of analytical data in the Journal of Clinical Microbiology ...

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field Inflammatix receives an ...

First Interventional Study Designed to Demonstrate the Clinical Utility of the TriVerity Test and its Impact on Patient Management "As the first interventional study to demonstrate the clinical ...

Company Reaches Important Product Development Milestone with its Myrna™ Instrument and TriVerity Cartridge SUNNYVALE, Calif., Nov. 15, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular ...

SUNNYVALE, Calif., Oct. 1, 2024 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today presented data demonstrating the high diagnostic and prognostic accuracy of the company's ...

Microscopy image showing red blood cells and bacteria caught in a web of fibrin threads. Composite colored scanning electron micrograph of sepsis blood clotting. The clots can damage or destroy tissue ...

SUNNYVALE, Calif., Nov. 11, 2024 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today announced initiation of the TriVerity™ for Improved Management of Emergency Department ...